138 related articles for article (PubMed ID: 35108028)
1. Revisiting
Emery LP; Brooks GA
JCO Oncol Pract; 2022 Apr; 18(4):281-282. PubMed ID: 35108028
[No Abstract] [Full Text] [Related]
2. Pharmacogenetic impact of UGT1A1 polymorphisms on pulmonary neuroendocrine tumours treated with metronomic irinotecan-based chemotherapy in Chinese populations.
Ma X; Han S; Liu Y; Liu JT; Fang J; Zhang YH
J Pharm Pharmacol; 2020 Nov; 72(11):1528-1535. PubMed ID: 32737884
[TBL] [Abstract][Full Text] [Related]
3. All You Need to Know About
Karas S; Innocenti F
JCO Oncol Pract; 2022 Apr; 18(4):270-277. PubMed ID: 34860573
[TBL] [Abstract][Full Text] [Related]
4. Precision Medicine:
Carrato A
JCO Oncol Pract; 2022 Apr; 18(4):278-280. PubMed ID: 35061524
[No Abstract] [Full Text] [Related]
5. Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype.
Páez D; Tobeña M; Fernández-Plana J; Sebio A; Virgili AC; Cirera L; Barnadas A; Riera P; Sullivan I; Salazar J
Br J Cancer; 2019 Jan; 120(2):190-195. PubMed ID: 30585257
[TBL] [Abstract][Full Text] [Related]
6. Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: Ready for prime time.
Hulshof EC; Deenen MJ; Guchelaar HJ; Gelderblom H
Eur J Cancer; 2020 Dec; 141():9-20. PubMed ID: 33125947
[TBL] [Abstract][Full Text] [Related]
7. [The risk of adverse events of CPT- 11].
Imataka H; Sekikawa T; Ichikawa W
Nihon Rinsho; 2016 Nov; 74(11):1847-1851. PubMed ID: 30550693
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.
Ando Y; Saka H; Ando M; Sawa T; Muro K; Ueoka H; Yokoyama A; Saitoh S; Shimokata K; Hasegawa Y
Cancer Res; 2000 Dec; 60(24):6921-6. PubMed ID: 11156391
[TBL] [Abstract][Full Text] [Related]
9. UGT1A1 polymorphism has a prognostic effect in patients with stage IB or II uterine cervical cancer and one or no metastatic pelvic nodes receiving irinotecan chemotherapy: a retrospective study.
Matsuoka H; Murakami R; Abiko K; Yamaguchi K; Horie A; Hamanishi J; Baba T; Mandai M
BMC Cancer; 2020 Aug; 20(1):729. PubMed ID: 32758288
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer.
Gold HT; Hall MJ; Blinder V; Schackman BR
Cancer; 2009 Sep; 115(17):3858-67. PubMed ID: 19517472
[TBL] [Abstract][Full Text] [Related]
11. Association between UGT1A1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the third-line treatment for advanced gastric cancer.
Yamaguchi T; Iwasa S; Shoji H; Honma Y; Takashima A; Kato K; Hamaguchi T; Higuchi K; Boku N
Gastric Cancer; 2019 Jul; 22(4):778-784. PubMed ID: 30603911
[TBL] [Abstract][Full Text] [Related]
12. Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question.
Deeken JF; Slack R; Marshall JL
Cancer; 2008 Oct; 113(7):1502-10. PubMed ID: 18720361
[TBL] [Abstract][Full Text] [Related]
13. [UGT1A1 Genotyping for Proper Use of Irinotecan].
Matsuoka A; Ando Y
Rinsho Byori; 2015 Jul; 63(7):876-82. PubMed ID: 26591441
[TBL] [Abstract][Full Text] [Related]
14. Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang.
Chen S; Hua L; Feng C; Mo Q; Wei M; Shen Y; Lin Z; Li G; Xu J; Guo C; Huang H
BMC Gastroenterol; 2020 Apr; 20(1):96. PubMed ID: 32264830
[TBL] [Abstract][Full Text] [Related]
15. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.
Hoskins JM; Goldberg RM; Qu P; Ibrahim JG; McLeod HL
J Natl Cancer Inst; 2007 Sep; 99(17):1290-5. PubMed ID: 17728214
[TBL] [Abstract][Full Text] [Related]
16. Impact of single-heterozygous UGT1A1 on the clinical outcomes of irinotecan monotherapy after fluoropyrimidine and platinum-based combination therapy for gastric cancer: a multicenter retrospective study.
Nakano S; Yuki S; Kawamoto Y; Nakatsumi H; Ando T; Kajiura S; Yoshikawa A; Harada K; Hatanaka K; Tanimoto A; Ishiguro A; Honda T; Dazai M; Sasaki T; Sakamoto N; Komatsu Y
Int J Clin Oncol; 2020 Oct; 25(10):1800-1806. PubMed ID: 32666389
[TBL] [Abstract][Full Text] [Related]
17. Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.
Campbell JM; Stephenson MD; Bateman E; Peters MD; Keefe DM; Bowen JM
Pharmacogenomics J; 2017 Jan; 17(1):21-28. PubMed ID: 27503581
[TBL] [Abstract][Full Text] [Related]
18. [Interest of UGT1A1 genotyping within digestive cancers treatment by irinotecan].
Boyer JC; Etienne-Grimaldi MC; Thomas F; Quaranta S; Picard N; Loriot MA; Poncet D; Gagnieu MC; Ged C; Broly F; Le Morvan V; Bouquié R; Gaub MP; Philibert L; Ghiringhelli F; Le Guellec C
Bull Cancer; 2014 Jun; 101(6):533-53. PubMed ID: 24977443
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and Pharmacogenetic Markers of Irinotecan Toxicity.
Hahn RZ; Antunes MV; Verza SG; Perassolo MS; Suyenaga ES; Schwartsmann G; Linden R
Curr Med Chem; 2019; 26(12):2085-2107. PubMed ID: 29932028
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics and irinotecan therapy.
Hahn KK; Wolff JJ; Kolesar JM
Am J Health Syst Pharm; 2006 Nov; 63(22):2211-7. PubMed ID: 17090741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
